Pharma Equity Group A/S Cl A (CO:PEG) — Stock Price
Pharma Equity Group A/S Cl A (CO:PEG) is currently trading at Dkr0.09 DKK, up 4.41% today. Over the past 52 weeks, shares have ranged between Dkr0.07 and Dkr0.15. This page tracks Pharma Equity Group A/S Cl A's live share price on the CO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Pharma Equity Group A/S Cl A market capitalisation.
Pharma Equity Group A/S Cl A (PEG) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Pharma Equity Group A/S Cl A's daily closing share price and trading volume on the CO exchange over the past year, giving a clear view of recent price momentum and liquidity.
Pharma Equity Group A/S Cl A Income Statement — Revenue, Profit & Earnings by Year
Pharma Equity Group A/S Cl A's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | Dkr0.00 | Dkr0.00 | Dkr0.00 | Dkr0.00 | Dkr0.00 |
| Cost of Revenue | Dkr311.00K | Dkr235.00K | Dkr480.00K | Dkr0.00 | — |
| Gross Profit | Dkr-311.00K | Dkr-235.00K | Dkr-480.00K | Dkr0.00 | — |
| Research & Development | Dkr5.12 Million | Dkr9.00 Million | Dkr8.82 Million | Dkr5.50K | — |
| SG&A | Dkr12.05 Million | Dkr12.29 Million | Dkr11.81K | Dkr1.98 Million | Dkr1.44 Million |
| Total Operating Expenses | Dkr24.98 Million | Dkr21.05 Million | Dkr24.81 Million | Dkr-3.03 Million | Dkr-4.91 Million |
| Operating Income | Dkr-25.29 Million | Dkr-21.29 Million | Dkr-25.29 Million | Dkr3.03 Million | Dkr-1.44 Million |
| EBITDA | Dkr-24.98 Million | Dkr-21.04 Million | Dkr-24.80 Million | Dkr4.47 Million | Dkr6.06 Million |
| EBIT | Dkr-25.29 Million | Dkr-21.27 Million | Dkr-25.28 Million | Dkr4.47 Million | Dkr5.82 Million |
| Interest Expense | Dkr2.65 Million | Dkr4.96 Million | Dkr1.56 Million | Dkr996.00K | Dkr665.00K |
| Income Before Tax | Dkr-26.41 Million | Dkr-26.24 Million | Dkr-26.84 Million | Dkr3.48 Million | Dkr5.39 Million |
| Income Tax Expense | Dkr-1.03 Million | Dkr-1.81 Million | Dkr-2.23 Million | Dkr-7.30 Million | Dkr-6.35 Million |
| Net Income | Dkr-25.38 Million | Dkr-24.42 Million | Dkr-24.61 Million | Dkr3.48 Million | Dkr5.39 Million |
Pharma Equity Group A/S Cl A Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Pharma Equity Group A/S Cl A's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | Dkr38.90 Million | Dkr65.61 Million | Dkr67.74 Million | Dkr71.07 Million | Dkr63.65 Million |
| Total Current Assets | Dkr38.26 Million | Dkr65.33 Million | Dkr67.23 Million | Dkr71.07 Million | Dkr145.00K |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | Dkr37.18 Million | Dkr60.29 Million | Dkr4.58 Million | Dkr70.89 Million | Dkr145.00K |
| Inventory | — | — | Dkr1.00K | Dkr1.59K | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | Dkr13.43 Million | Dkr16.73 Million | Dkr42.40 Million | Dkr25.03 Million | Dkr21.08 Million |
| Total Current Liabilities | Dkr8.83 Million | Dkr8.63 Million | Dkr34.33 Million | Dkr25.03 Million | Dkr14.50 Million |
| Long-term Debt | Dkr4.18 Million | Dkr8.10 Million | Dkr7.84 Million | Dkr0.00 | Dkr6.58 Million |
| Net Debt | Dkr7.56 Million | Dkr9.50 Million | Dkr25.99 Million | Dkr22.66 Million | Dkr18.93 Million |
| Total Stockholder Equity | Dkr25.47 Million | Dkr48.88 Million | Dkr25.33 Million | Dkr46.05 Million | Dkr42.57 Million |
| Retained Earnings | — | — | — | Dkr27.39 Million | Dkr23.91 Million |
Pharma Equity Group A/S Cl A Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Pharma Equity Group A/S Cl A generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | Dkr-17.66 Million | Dkr-22.86 Million | Dkr-16.62 Million | Dkr-2.87 Million | Dkr-2.09 Million |
| Capital Expenditures | Dkr17.66 Million | Dkr0.00 | Dkr73.00K | Dkr0.00 | Dkr0.00 |
| Free Cash Flow | Dkr-17.66 Million | Dkr-22.86 Million | Dkr-16.70 Million | Dkr-2.87 Million | Dkr-2.09 Million |
| Investing Cash Flow | Dkr11.00K | — | Dkr-73.00K | — | — |
| Financing Cash Flow | Dkr13.91 Million | Dkr22.86 Million | Dkr17.06 Million | Dkr3.06 Million | Dkr2.09 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | — | — | Dkr0.00 | Dkr217.00 | — |
| Depreciation | Dkr311.00K | Dkr235.00K | Dkr480.00K | Dkr539.00 | — |
| Change in Cash | Dkr-3.74 Million | Dkr3.00K | Dkr1.40 Million | Dkr182.00K | Dkr0.00 |
Pharma Equity Group A/S Cl A Earnings History — EPS Actual vs. Analyst Estimates
Track Pharma Equity Group A/S Cl A's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 20, 2025 | -0.02 | 0.00 | — |
| Nov 15, 2024 | -0.01 | -0.01 | +0.00% |
| Aug 16, 2024 | -0.01 | 0.00 | — |
| May 16, 2024 | -0.01 | -0.01 | +0.00% |
| Mar 29, 2024 | -0.01 | 0.00 | — |
| Nov 16, 2023 | 0.00 | 0.00 | — |
| Aug 16, 2023 | 0.00 | — | — |
| May 11, 2023 | -0.15 | — | — |